Recent Challenges Demand Innovative Approaches to Surface Disinfections

NEW YORK, Dec. 17, 2020 /PRNewswire/ -- Due to the pandemic's rapid spread earlier this year, the U.S. EPA (Environment Protection Agency) accelerated its review process of submissions by disinfectant manufacturers. The EPA also took steps to avoid supply chain challenges by making the process of obtaining inert ingredients more flexible. It even allowed for some active ingredients listed in List N – "Disinfectants for Use Against SARS-CoV-2," to be obtained without checking for the agency's approval. Overall, according to data provided by The Business Research Company, the global sterilization equipment and disinfectants market size is expected to grow from USD 7,142.3 Million in 2019 to USD 9,846.9 Million in 2023 at a compound annual growth rate (CAGR) of 8.4%. In 2020, the sterilization equipment market size was valued at USD 8,049.3 Million, driven by increased demand for sterilization equipment, disinfectants, and critical care equipment due to the pandemic. Optec International, Inc. (OTC: OPTI), Novan, Inc. (NASDAQ: NOVN), Trevena, Inc. (NASDAQ: TRVN), VBI Vaccines Inc. (NASDAQ: VBIV), Amneal Pharmaceuticals, Inc. (NYSE: AMRX)

Furthermore, new disinfecting technology has begun to appear, utilizing UV light. For example, Seoul Viosys, a compound semiconductor solution provider, has said that its 'Violeds' technology has been applied to an escalator handrail sterilization solution that is being supplied to leading global escalator and elevator OEMs by EHC Global Inc. ("EHC"), a Canadian-based manufacturer of integrated solutions for the vertical transportation industry. Violeds is a clean technology that provides robust disinfection on the surface of handrails using UV LED light. It is optimally designed to match the speed, area, and distance of the handrail to disinfect 99.9% of harmful viruses and bacteria in the areas exposed to the light. "In response to the growing demand for vertical transportation solutions incorporating clean, antibacterial and disinfection technologies, EHC has implemented the Violeds UVC disinfection module by Seoul Viosys, the leading UV LED company," said Patrick Bothwell, Vice President of Sales, EHC Global. "Thousands of installations have already been completed and we anticipate continued demand in 2021 and beyond."

Optec International, Inc. (OTC: OPTI) just announced breaking news that, "it will be holding the annual shareholder call via Zoom on December 29, 2020.  

CEO, Roger Pawson, stated 'We have decided to schedule the annual shareholder call at the end of this month to review the company's 2020 overall status.                                                                                                      

Please email your questions to: and we will address as many of the questions as we can during the call'.

The purpose of the call is to provide a year-end update of the company's progress and growth and answer pending questions to provide clarity and future expectations to our shareholders. The Company will post the call-in details via press release and on the website prior to the call.  Furthermore, an audio copy of the shareholder call will be published on for the benefit of shareholders who cannot attend on December 29, 2020 will still be able to hear all that will be discussed.

About OPTEC International, Inc: With Locations in Carlsbad and Vista, California, OPTEC International is a developer and manufacturer of electronic LED, Ultraviolet (UV) & UV-C safety products and related advanced technologies and PPE (Personal Protection Equipment) products. The company's Safe-Scan product line is being launched at a time when HR directors and facilities managers are experiencing extreme concern with respect to keeping environments safe during the global pandemic crisis and the safe reopening of the U.S. economy. For more information visit:"

For our latest "Buzz on the Street" Show featuring Optec International, Inc., Ltd. recent corporate news, please head over to:

Novan, Inc. (NASDAQ: NOVN) reported earlier this year that it has engaged Strategic LinkAssoc. to manage the supply chain, logistics and manufacturing of Vystar's Rx3000®, a hybridultraviolet (UV) light and HEPA filter air purification system that is FDA certified as a Class IIMedical Device, designed for use in healthcare facilities. The relationship with Strategic Link and its supply and manufacturing network enables significantly increased production capacity to meet the growing demand for RXair® purification products that reduce airborne viruses and bacteria, such as coronavirus strains, influenza and pneumonia. "As facility managers work to ensure the air in their facilities is safe, we are fielding requests for far more Rx3000 units than we could produce in-house," stated Steve Rotman, CEO of Vystar. "Strategic Link has brought together high quality, experienced suppliers and manufacturers who are considered essential businesses and have continued operations during the COVID shutdown. This will enable us to have a reliable supply chain and a top quality finished product that is 'Made in the USA'."

Trevena, Inc. (NASDAQ: TRVN) announced on August 24th that the Imperial College London (ICL) has initiated a proof-of-concept study for TRV027 in COVID-19 patients. Through an ongoing collaboration with ICL, the Company is evaluating the potential of TRV027 to treat acute lung damage / abnormal blood clotting associated with COVID-19. ICL is sponsoring and funding the study, with additional support through the British Heart Foundation Centre for Research Excellence Award.  "I am very pleased that Imperial College London has reached this important milestone of trial initiation," said Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. "As the global search for solutions to combat the COVID-19 pandemic continues, there remains an urgent need for new therapies that can prevent the severe multi-organ damage caused by the virus. TRV027 represents a uniquely targeted approach to potentially treating some of the serious and deadly complications associated with COVID-19."

VBI Vaccines Inc. (NASDAQ: VBIV) announced on August 26th, data from three preclinical mouse studies conducted to enable selection of optimized clinical candidates for the company's coronavirus program, VBI-2900. As a result of these studies, VBI has selected two vaccine candidates, with the potential to be one-dose vaccines, to take into an adaptive Phase 1/2 human clinical study, expected to begin around year-end 2020, subject to regulatory approval: (1) VBI-2901, a trivalent pan-coronavirus vaccine candidate expressing the SARS-CoV-2 (COVID-19), SARS-CoV (SARS), and MERS-CoV (MERS) spike proteins; and (2) VBI-2902, a monovalent vaccine candidate expressing the SARS-CoV-2 (COVID-19) spike protein.  "We are excited to announce these impressive pre-clinical data, which we believe clearly support the advancement of the two vaccine candidates, VBI-2901 and VBI-2902, into human clinical studies around the end of the year," said Jeff Baxter, VBI's President and CEO. "An effective solution to the ongoing COVID-19 pandemic will require a vaccine that is capable of providing robust protection, quickly. Based on the data seen to-date, we believe the VBI-2900 program has the potential to be administered as a one-dose vaccine regimen at human doses ranging from 2-5mcg, and, further, VBI-2901 may offer increased breadth of reactivity across a broader range of coronaviruses. We are very encouraged by these results and remain deeply committed to addressing this devastating public health crisis."

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced on March 20th, that it is responding to the national COVID-19 health emergency by building on its existing supply of hydroxychloroquine sulfate.  "This is a critical time in the fight against COVID-19," said Chirag and Chintu Patel, Co-Chief Executive Officers. "With our existing supply of hydroxychloroquine sulfate, and the ability to fast-track production, Amneal is well-positioned to help meet the potential demand for patients in need. We are grateful to our employees for working to accelerate production and will continue to do everything we can to support the healthcare needs of our communities."

Subscribe Now! Watch us report LIVE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. has not been compensated directly by any of the companies mentioned here in this editorial unless mentioned otherwise. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For optec international, inc. video production, filming editing, news reporting, financial and corporate news dissemination, has been compensated three thousand dollars by cambridge consulting inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:

Media Contact:

Cision View original content:


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.